Back

SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?

European Heart Journal

20 March 2020
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY Pharmacology and Pharmacotherapy

Abstract

Abstract

Contributors

Gabriela M Kuster
Gabriela M Kuster

Author

University Hospital Basel Basel , Switzerland

Otmar Pfister
Otmar Pfister

Author

Thilo Burkard
Thilo Burkard

Author

Qian Zhou
Qian Zhou

Author

University Hospital Basel Basel , Switzerland

Raphael Twerenbold
Raphael Twerenbold

Author

University Heart and Vascular Centre Hamburg (UHZ) Hamburg , Germany

Philip Haaf
Philip Haaf

Author

Andreas F Widmer
Andreas F Widmer

Author

Stefan Osswald
Stefan Osswald

Author

University of Basel Basel , Switzerland

You may be interested in
thumbnail
Congress Presentation
COVID-19-induced heart failure: pathophysiologic mechanisms, and their relevance to clinical practice.
21 May 2022
thumbnail
Congress Presentation
Clinical, remodeling and hemodynamic effects of renin-angiotensin-aldosterone system inhibitors among patients on left ventricular assist device support
20 May 2023
thumbnail
Congress Presentation
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
26 August 2022
thumbnail
Congress Presentation
Argentine registry of acute heart failure, reality in times of pandemic
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources